138 related articles for article (PubMed ID: 25436004)
1. Expression characteristics of
Chang Z; Zhang W; Chang Z; Song M; Qin Y; Chang F; Guo H; Wei Q
Oncol Lett; 2015 Jan; 9(1):430-436. PubMed ID: 25436004
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma.
Koda M; Yashima K; Kawaguchi K; Andachi H; Hosoda A; Shiota G; Ito H; Murawaki Y
Cancer Lett; 2003 Sep; 199(2):131-8. PubMed ID: 12969785
[TBL] [Abstract][Full Text] [Related]
3. Expression of methylation-modulated tumor-related genes in endoscopically resected early esophageal squamous neoplasia.
Hosoda K; Yashima K; Tamoto A; Yamamoto S; Kawata S; Ikebuchi Y; Matsumoto K; Kawaguchi K; Harada K; Murawaki Y; Isomoto H
Oncol Lett; 2017 Jul; 14(1):737-742. PubMed ID: 28693228
[TBL] [Abstract][Full Text] [Related]
4. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
5. Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms.
Yasugi A; Yashima K; Hara A; Koda M; Kawaguchi K; Harada K; Andachi H; Murawaki Y
Oncol Rep; 2008 Jan; 19(1):41-7. PubMed ID: 18097574
[TBL] [Abstract][Full Text] [Related]
6. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
7. [Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance].
Yao CC; Lin CY; Hu MB
Ai Zheng; 2004 Mar; 23(3):310-6. PubMed ID: 15025965
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.
Tamoto A; Yashima K; Hosoda K; Yamamoto S; Kawata S; Ikebuchi Y; Matsumoto K; Kawaguchi K; Harada K; Murawaki Y; Isomoto H
Oncol Lett; 2017 Sep; 14(3):3683-3688. PubMed ID: 28927131
[TBL] [Abstract][Full Text] [Related]
9. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
10. Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype.
Kawaguchi K; Yashima K; Koda M; Tsutsumi A; Kitaoka S; Andachi H; Hosoda A; Kishimoto Y; Shiota G; Ito H; Murawaki Y
Br J Cancer; 2004 Feb; 90(3):672-7. PubMed ID: 14760383
[TBL] [Abstract][Full Text] [Related]
11. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix.
Giarnieri E; Mancini R; Pisani T; Alderisio M; Vecchione A
Clin Cancer Res; 2000 Sep; 6(9):3600-6. PubMed ID: 10999751
[TBL] [Abstract][Full Text] [Related]
12. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.
Andachi H; Yashima K; Koda M; Kawaguchi K; Kitamura A; Hosoda A; Kishimoto Y; Shiota G; Ito H; Makino M; Kaibara N; Kawasaki H; Murawaki Y
Br J Cancer; 2002 Aug; 87(4):441-5. PubMed ID: 12177781
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
[TBL] [Abstract][Full Text] [Related]
14. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
15. Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development.
Yu Y; Liu X; Yang Y; Zhao X; Xue J; Zhang W; Yang A
Oncol Lett; 2015 Jul; 10(1):392-398. PubMed ID: 26171037
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
Segawa T; Sasagawa T; Saijoh K; Inoue M
Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
[TBL] [Abstract][Full Text] [Related]
17. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53.
Mascaux C; Martin B; Verdebout JM; Meert AP; Ninane V; Sculier JP
Eur Respir J; 2003 May; 21(5):753-8. PubMed ID: 12765416
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer.
Chava S; Mohan V; Shetty PJ; Manolla ML; Vaidya S; Khan IA; Waseem GL; Boddala P; Ahuja YR; Hasan Q
Dis Esophagus; 2012 Jan; 25(1):81-7. PubMed ID: 21668571
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological analysis of loss of fragile histidine triad expression in lung cancer].
Zhao P; Lv Y; Zhong M; Chen L
Zhongguo Fei Ai Za Zhi; 2002 Oct; 5(5):345-8. PubMed ID: 21329602
[TBL] [Abstract][Full Text] [Related]
20. Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition.
Cao J; Chen XP; Li WL; Xia J; Du H; Tang WB; Wang H; Chen XW; Xiao HQ; Li YY
World J Gastroenterol; 2007 Feb; 13(7):1018-26. PubMed ID: 17373735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
